C5a Protein, Human, Recombinant


C5a Protein, Human, Recombinant: Product Information

> 94 % as determined by SDS-PAGE
Please contact us for more information.
Measured by its ability to induce N-acetyl-β-D-glucosaminidase release from differentiated U937 human histiocytic lymphoma cells. The ED50 for this effect is typically 5-15 ng/ml.
Protein Construction
A DNA sequence encoding the active form of human C5a (Leu 679-Arg 751) was expressed.
Expressed Host
E. coli
Predicted N Terminal
Based on N-terminal sequencing analysis, the first 7 aa of C5a is: MLQKKIE
Molecule Mass
The recombinant human C5a consists of 74 amino acids and has a predicted molecular mass of 8.3 kDa which is also estimated by SDS-PAGE.
Lyophilized from sterile PBS, pH 7.4
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

C5a Protein, Human, Recombinant: Images

Measured by its ability to induce N-acetyl-β-D-glucosaminidase release from differentiated U937 human histiocytic lymphoma cells. The ED50 for this effect is typically 5-15 ng/ml.

C5a Protein, Human, Recombinant: Synonyms

C5a Protein, Human; C5b Protein, Human; C5D Protein, Human; C5Da Protein, Human; Complement 5a Protein, Human; CPAMD4 Protein, Human; ECLZB Protein, Human

C5a Background Information

C5a is a protein fragment released from complement component C5. This 74 amino acid peptide in humans is generated by the cleavage of C5a convertase on the C5 α-chain during the classical, alternative, and lectin pathways of complement activation. The structure of C5a includes a core region consisting of four, anti-parallel alpha-helices held together by three disulfide linkages and a structured C-terminal tail, and C5a is rapidly metabolised by carboxypeptidase B to a 73 amino acid low activity form, C5a des-Arg. C5a is an extremely potent proinflammatory mediator, as well as a potent chemotactic factor for neutrophils and other leukocytes. It causes histamine release, increases in vascular permeability, induces several cytokines production from leukocytes, enhances neutrophil-endothelial cell adhesion, and augments the humoral and cell-mediated immune response. C5a is quickly metabolised by carboxypeptidases, forming the less potent C5adesArg. Acting via a classical G protein-coupled receptor, CD88, C5a and C5adesArg exert a number of effects essential to the innate immune response, while their actions at the more recently discovered non-G protein-coupled receptor, C5L2 (or GPR77), remain unclear. The widespread expression of C5a receptors throughout the body allows C5a to elicit a broad range of effects. Thus, C5a has been found to be a significant pathogenic driver in a number of immuno-inflammatory diseases, making C5a inhibition an attractive therapeutic strategy. C5a is a strong chemoattractant and is involved in the recruitment of inflammatory cells such as neutrophils, eosinophils, monocytes, and T lymphocytes, in activation of phagocytic cells and release of granule-based enzymes and generation of oxidants, all of which may contribute to innate immune functions or tissue damage. Accordingly, the anaphylatoxin C5a is implicated in a variety of diseases such as rheumatoid arthritis, systemic lupus erythematosus, reperfusion injury, Alzheimer's disease, and sepsis.
Full Name
complement component 5
Related Pathways
  • Complement Activation Pathways
    Complement Activation Pathways
  • Guo RF, et al.. (2005) Role of C5a in inflammatory responses. Annu Rev Immunol. 23: 821-52.
  • Guo RF, et al. (2006) C5a, a therapeutic target in sepsis. Recent Pat Antiinfect Drug Discov. 1(1): 57-65.
  • Manthey HD, et al. (2009) Complement component 5a (C5a). Int J Biochem Cell Biol. 41(11): 2114-7.
  • Inflammatory responses induced by lipopolysaccharide are amplified in primary human monocytes but suppressed in macrophages by complement protein C5a
    V Seow, J Lim, A Iyer, JY Suen, JK Ariffin…
    The Journal of Immunology
  • Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists
    Seow, V;Lim, J;Cotterell, AJ;Yau, MK;Xu, W;Lohman, RJ;Kok, WM;Stoermer, MJ;Sweet, MJ;Reid, RC;Suen, JY;Fairlie, DP;
    Sci Rep
  • Partial ligand-receptor engagement yields functional bias at the human complement receptor, C5aR1
    Pandey, S;Li, X;Srivastava, A;Baidya, M;Kumari, P;
  • Dynamic Transcriptome-Proteome Correlation Networks Reveal Human Myeloid Differentiation and Neutrophil-Specific Programming
    Hoogendijk, AJ;Pourfarzad, F;Aarts, CEM;Tool, ATJ;Hiemstra, IH;Grassi, L;Frontini, M;Meijer, AB;van den Biggelaar, M;Kuijpers, TW;
    Cell Rep
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.